SVCM
XENE icon

Saturn V Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Saturn V Capital Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-503,701
Closed -$20.2M – 24
2025
Q3 		$20.2M Buy
503,701
+35,337
+8% +$1.24M 4.44% 11
2025
Q2 		$14.7M Buy
468,364
+54,653
+13% +$1.78M 5.94% 8
2025
Q1 		$13.9M Buy
413,711
+91,241
+28% +$3.46M 7% 4
2024
Q4 		$12.6M Buy
+322,470
New +$13.3M 4.95% 10

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Saturn V Capital Management's XENE Position: Q4 2025 in Review

Saturn V Capital Management sold out of Xenon Pharmaceuticals (XENE) in Q4 2025, closing a stake of 503,701 shares — an estimated $20.2M sold.

Saturn V Capital Management first reported a position in XENE in Q4 2024 and held it in 4 quarters. The position peaked at $20.2M in Q3 2025. 245 funds tracked by Wall St. Rank hold XENE as of Q4 2025.

  • Saturn V Capital Management reported no remaining Xenon Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Saturn V Capital Management sold 503,701 Xenon Pharmaceuticals shares in Q4 2025, an estimated $20.2M.
  • Saturn V Capital Management first reported a position in Xenon Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • Saturn V Capital Management's Xenon Pharmaceuticals position peaked at $20.2M in Q3 2025.
  • 245 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2025.

Based on Saturn V Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.